首页 > 最新文献

Pediatric Diabetes最新文献

英文 中文
ISPAD Clinical Practice Consensus Guidelines 2022: Psychological care of children, adolescents and young adults with diabetes. ISPAD临床实践共识指南2022:儿童、青少年和青年糖尿病患者的心理护理。
IF 3.4 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-12-01 DOI: 10.1111/pedi.13428
Maartje de Wit, Katarzyna A Gajewska, Eveline R Goethals, Vincent McDarby, Xiaolei Zhao, Given Hapunda, Alan M Delamater, Linda A DiMeglio
several
{"title":"ISPAD Clinical Practice Consensus Guidelines 2022: Psychological care of children, adolescents and young adults with diabetes.","authors":"Maartje de Wit, Katarzyna A Gajewska, Eveline R Goethals, Vincent McDarby, Xiaolei Zhao, Given Hapunda, Alan M Delamater, Linda A DiMeglio","doi":"10.1111/pedi.13428","DOIUrl":"https://doi.org/10.1111/pedi.13428","url":null,"abstract":"several","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"23 8","pages":"1373-1389"},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/78/66/PEDI-23-1373.PMC10107478.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9833279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 15
Type 1 diabetes knowledge assessment: The KAT-1 validation study. 1型糖尿病知识评估:KAT-1验证研究。
IF 3.4 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-12-01 DOI: 10.1111/pedi.13414
Anastasia Albanese-O'Neill, Jann MacInnes, Michael J Haller, Janey Adams, Nicole Thomas, Angelina Bernier

Objective: This study sought to examine the reliability and validity of a novel pediatric type 1 diabetes knowledge assessment (KAT-1) designed for children, adolescents, young adults and their parents/guardians. The instrument was designed to be integrated into the clinic workflow to obtain objective data electronically.

Research design and methods: KAT-1 was developed by a multidisciplinary team and includes 11 independent topical subscales. Forty children/caregivers participated in a pilot study; their feedback was used to improve item clarity and readability. Subsequently, a validation study was performed in 200 participants (100 children/adolescents/young adults with type 1 diabetes ages 11-21 years and 100 parents/guardians of children with type 1 diabetes ages 1-15 years) to examine correlations between the KAT-1 scores and Revised Diabetes Knowledge Test (DKT2) scores and HbA1c. An item analysis was conducted to determine internal consistency and reliability; topical subscales were evaluated using Cronbach's alpha.

Results: Total KAT-1 scores were positively correlated with DKT2 scores r = 0.674, p < 0.001, and negatively correlated with HbA1c, r = -0.3, p < 0.001. All KAT-1 subscales were positively and significantly correlated with one another and with total KAT-1 score. Internal consistency of total KAT-1 score was strong (Cronbach's α = 0.938, mean score 84.6, SD = 16.1) and 9 of 11 independent topical subscales demonstrated strong internal consistency. Completion time for subscales was <5 min.

Conclusions: KAT-1 is a valid instrument to assess type 1 diabetes knowledge. The instrument's short topical subscales can be used to objectively assess specific knowledge and individualize diabetes education. KAT-1 has been integrated into our electronic health record (EPIC) and is available online at no cost.

目的:本研究旨在检验为儿童、青少年、年轻人及其父母/监护人设计的新型儿科1型糖尿病知识评估(KAT-1)的信度和效度。该仪器被设计为集成到临床工作流程中,以电子方式获取客观数据。研究设计和方法:KAT-1由一个多学科团队开发,包括11个独立的主题子量表。40名儿童/照料者参加了一项试点研究;他们的反馈被用来提高项目的清晰度和可读性。随后,在200名参与者中进行了一项验证研究(100名11-21岁的1型糖尿病儿童/青少年/年轻人和100名1-15岁1型糖尿病儿童的父母/监护人),以检查KAT-1分数和修订糖尿病知识测试(DKT2)分数和HbA1c之间的相关性。进行项目分析以确定内部一致性和信度;局部分量表采用Cronbach's alpha进行评估。结果:KAT-1总分与DKT2总分呈正相关(r = 0.674, p)。结论:KAT-1总分是评估1型糖尿病知识的有效工具。该工具的短主题分量表可用于客观评估特定知识和个性化糖尿病教育。KAT-1已集成到我们的电子健康记录(EPIC)中,并可免费在线获取。
{"title":"Type 1 diabetes knowledge assessment: The KAT-1 validation study.","authors":"Anastasia Albanese-O'Neill,&nbsp;Jann MacInnes,&nbsp;Michael J Haller,&nbsp;Janey Adams,&nbsp;Nicole Thomas,&nbsp;Angelina Bernier","doi":"10.1111/pedi.13414","DOIUrl":"https://doi.org/10.1111/pedi.13414","url":null,"abstract":"<p><strong>Objective: </strong>This study sought to examine the reliability and validity of a novel pediatric type 1 diabetes knowledge assessment (KAT-1) designed for children, adolescents, young adults and their parents/guardians. The instrument was designed to be integrated into the clinic workflow to obtain objective data electronically.</p><p><strong>Research design and methods: </strong>KAT-1 was developed by a multidisciplinary team and includes 11 independent topical subscales. Forty children/caregivers participated in a pilot study; their feedback was used to improve item clarity and readability. Subsequently, a validation study was performed in 200 participants (100 children/adolescents/young adults with type 1 diabetes ages 11-21 years and 100 parents/guardians of children with type 1 diabetes ages 1-15 years) to examine correlations between the KAT-1 scores and Revised Diabetes Knowledge Test (DKT2) scores and HbA1c. An item analysis was conducted to determine internal consistency and reliability; topical subscales were evaluated using Cronbach's alpha.</p><p><strong>Results: </strong>Total KAT-1 scores were positively correlated with DKT2 scores r = 0.674, p < 0.001, and negatively correlated with HbA1c, r = -0.3, p < 0.001. All KAT-1 subscales were positively and significantly correlated with one another and with total KAT-1 score. Internal consistency of total KAT-1 score was strong (Cronbach's α = 0.938, mean score 84.6, SD = 16.1) and 9 of 11 independent topical subscales demonstrated strong internal consistency. Completion time for subscales was <5 min.</p><p><strong>Conclusions: </strong>KAT-1 is a valid instrument to assess type 1 diabetes knowledge. The instrument's short topical subscales can be used to objectively assess specific knowledge and individualize diabetes education. KAT-1 has been integrated into our electronic health record (EPIC) and is available online at no cost.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"23 8","pages":"1687-1694"},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10440504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery. ISPAD临床实践共识指南2022:糖尿病技术:胰岛素输送。
IF 3.4 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-12-01 DOI: 10.1111/pedi.13421
Jennifer L Sherr, Melissa Schoelwer, Tiago Jeronimo Dos Santos, Leenatha Reddy, Torben Biester, Alfonso Galderisi, Jacobus Cornelius van Dyk, Marisa E Hilliard, Cari Berget, Linda A DiMeglio
LGS is strongly recommended for all people with T1D to reduce the severity and duration of hypoglycemia. A
{"title":"ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery.","authors":"Jennifer L Sherr,&nbsp;Melissa Schoelwer,&nbsp;Tiago Jeronimo Dos Santos,&nbsp;Leenatha Reddy,&nbsp;Torben Biester,&nbsp;Alfonso Galderisi,&nbsp;Jacobus Cornelius van Dyk,&nbsp;Marisa E Hilliard,&nbsp;Cari Berget,&nbsp;Linda A DiMeglio","doi":"10.1111/pedi.13421","DOIUrl":"https://doi.org/10.1111/pedi.13421","url":null,"abstract":"LGS is strongly recommended for all people with T1D to reduce the severity and duration of hypoglycemia. A","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"23 8","pages":"1406-1431"},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10441131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 25
Issue Information 问题信息
IF 3.4 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-12-01 DOI: 10.1111/pedi.13228
{"title":"Issue Information","authors":"","doi":"10.1111/pedi.13228","DOIUrl":"https://doi.org/10.1111/pedi.13228","url":null,"abstract":"","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":" ","pages":""},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46905625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of plasma beta-hydroxybutyrate to define resolution of diabetic ketoacidosis. 血浆β -羟基丁酸测定糖尿病酮症酸中毒的疗效。
IF 3.4 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-12-01 Epub Date: 2022-10-29 DOI: 10.1111/pedi.13437
Elise Schlissel Tremblay, Kate Millington, Yunhong Wu, David Wypij, Yufan Yang, Michael S D Agus, Joseph Wolfsdorf

Background: Diabetic ketoacidosis (DKA) is a common, life-threatening complication of type 1 diabetes (T1D) characterized by unregulated ketogenesis caused by relative or absolute insulin deficiency. DKA management requires frequent biochemical monitoring. Plasma ß-hydroxybutyrate (BOHB) has not been included in traditional definitions of DKA resolution.

Objective: The aim of this study was to determine a cut-point level of BOHB to define DKA resolution in patients with T1D treated with intravenous (IV) insulin.

Subjects: We identified patients with T1D receiving IV insulin for DKA treatment at a quaternary children's hospital from January 1, 2017 through December 31, 2020 who had plasma measurements of BOHB after DKA onset and whose DKA resolved by traditional laboratory criteria (venous pH (vpH) ≥ 7.3, serum bicarbonate (HCO3 ) ≥ 15 mmol/L, and/or anion gap (AG) ≤ 14 mmol/L).

Methods: Associations between plasma BOHB and vpH, HCO3 , and AG were evaluated via scatterplots. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were used to evaluate BOHB cut-points to predict DKA resolution.

Results: We analyzed 403 patients with 471 unique encounters. Plasma BOHB showed the most robust relationship with AG. The ROC curve comparing plasma BOHB to the accepted definition of DKA resolution, AG ≤14 mmol/L, had an AUC of 0.92. A BOHB value of <1.5 mmol/L had a sensitivity of 83% and specificity of 87%; this cut-point correctly classified 86% of the observations.

Conclusions: A plasma BOHB value of <1.5 mmol/L can be used to define resolution of DKA.

背景:糖尿病酮症酸中毒(DKA)是一种常见的危及生命的1型糖尿病(T1D)并发症,其特征是由相对或绝对胰岛素缺乏引起的酮生成不调节。DKA管理需要经常进行生化监测。血浆ß-羟基丁酸(BOHB)未包括在DKA分辨率的传统定义中。目的:本研究的目的是确定BOHB的切点水平,以确定静脉注射(IV)胰岛素治疗的T1D患者的DKA消退。研究对象:我们确定了2017年1月1日至2020年12月31日在一家第四儿童医院接受静脉胰岛素治疗DKA的T1D患者,这些患者在DKA发病后进行了血浆BOHB测量,并且DKA通过传统实验室标准(静脉pH值(vpH)≥7.3,血清碳酸氢盐(HCO3)≥15 mmol/L,和/或阴离子间隙(AG)≤14 mmol/L)得到解决。方法:通过散点图评估血浆BOHB与vpH、HCO3和AG之间的关系。采用受试者工作特征(ROC)曲线和曲线下面积(AUC)评价BOHB切点,预测DKA分辨率。结果:我们分析了403例患者的471例独特遭遇。血浆BOHB与AG的关系最为密切。血浆BOHB与公认的DKA分辨率定义(AG≤14 mmol/L)的ROC曲线比较,AUC为0.92。结论:血浆BOHB值为
{"title":"Utility of plasma beta-hydroxybutyrate to define resolution of diabetic ketoacidosis.","authors":"Elise Schlissel Tremblay, Kate Millington, Yunhong Wu, David Wypij, Yufan Yang, Michael S D Agus, Joseph Wolfsdorf","doi":"10.1111/pedi.13437","DOIUrl":"10.1111/pedi.13437","url":null,"abstract":"<p><strong>Background: </strong>Diabetic ketoacidosis (DKA) is a common, life-threatening complication of type 1 diabetes (T1D) characterized by unregulated ketogenesis caused by relative or absolute insulin deficiency. DKA management requires frequent biochemical monitoring. Plasma ß-hydroxybutyrate (BOHB) has not been included in traditional definitions of DKA resolution.</p><p><strong>Objective: </strong>The aim of this study was to determine a cut-point level of BOHB to define DKA resolution in patients with T1D treated with intravenous (IV) insulin.</p><p><strong>Subjects: </strong>We identified patients with T1D receiving IV insulin for DKA treatment at a quaternary children's hospital from January 1, 2017 through December 31, 2020 who had plasma measurements of BOHB after DKA onset and whose DKA resolved by traditional laboratory criteria (venous pH (vpH) ≥ 7.3, serum bicarbonate (HCO<sub>3</sub> ) ≥ 15 mmol/L, and/or anion gap (AG) ≤ 14 mmol/L).</p><p><strong>Methods: </strong>Associations between plasma BOHB and vpH, HCO<sub>3</sub> , and AG were evaluated via scatterplots. Receiver operating characteristic (ROC) curves and area under the curve (AUC) were used to evaluate BOHB cut-points to predict DKA resolution.</p><p><strong>Results: </strong>We analyzed 403 patients with 471 unique encounters. Plasma BOHB showed the most robust relationship with AG. The ROC curve comparing plasma BOHB to the accepted definition of DKA resolution, AG ≤14 mmol/L, had an AUC of 0.92. A BOHB value of <1.5 mmol/L had a sensitivity of 83% and specificity of 87%; this cut-point correctly classified 86% of the observations.</p><p><strong>Conclusions: </strong>A plasma BOHB value of <1.5 mmol/L can be used to define resolution of DKA.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"23 8","pages":"1621-1627"},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772128/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10446943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents. ISPAD临床实践共识指南2022:儿童和青少年1型糖尿病的分期。
IF 3.4 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-12-01 DOI: 10.1111/pedi.13410
Rachel E J Besser, Kirstine J Bell, Jenny J Couper, Anette-G Ziegler, Diane K Wherrett, Mikael Knip, Cate Speake, Kristina Casteels, Kimberly A Driscoll, Laura Jacobsen, Maria E Craig, Michael J Haller
The stages of type 1 diabetes (T1D) provide common ground for global efforts to prevent DKA and delay progression to disease in children and adolescents: An ISPAD consensus guideline. with normal glucose tolerance (via OGTT); Stage 2=multiple AAb-positive with abnormal glucose tolerance; Stage 3=clinical diagnosis of T1D
{"title":"ISPAD Clinical Practice Consensus Guidelines 2022: Stages of type 1 diabetes in children and adolescents.","authors":"Rachel E J Besser,&nbsp;Kirstine J Bell,&nbsp;Jenny J Couper,&nbsp;Anette-G Ziegler,&nbsp;Diane K Wherrett,&nbsp;Mikael Knip,&nbsp;Cate Speake,&nbsp;Kristina Casteels,&nbsp;Kimberly A Driscoll,&nbsp;Laura Jacobsen,&nbsp;Maria E Craig,&nbsp;Michael J Haller","doi":"10.1111/pedi.13410","DOIUrl":"https://doi.org/10.1111/pedi.13410","url":null,"abstract":"The stages of type 1 diabetes (T1D) provide common ground for global efforts to prevent DKA and delay progression to disease in children and adolescents: An ISPAD consensus guideline. with normal glucose tolerance (via OGTT); Stage 2=multiple AAb-positive with abnormal glucose tolerance; Stage 3=clinical diagnosis of T1D","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"23 8","pages":"1175-1187"},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10499183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 40
Adolescent ambivalence about diabetes technology-The Janus faces of automated care. 青少年对糖尿病技术的矛盾心理——自动护理的两面脸。
IF 3.4 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-12-01 DOI: 10.1111/pedi.13423
Fergus J Cameron, Michael Arnold, John W Gregory

The Janus face metaphor approach highlights that a technology may simultaneously have two opposite faces or properties with unforeseen paradoxes within human-technology interaction. Suboptimal acceptance and clinical outcomes are sometimes seen in adolescents who use diabetes-related technologies. A traditional linear techno-determinist model of technology use would ascribe these unintended outcomes to suboptimal technology, suboptimal patient behavior, or suboptimal outcome measures. This paradigm has demonstratively not been successful at universally improving clinical outcomes over the last two decades. Alternatively, the Janus face metaphor moves away from a linear techno-determinist model and focuses on the dynamic interaction of the human condition and technology. Specifically, it can be used to understand variance in adoption or successful use of diabetes-related technology and to retrospectively understand suboptimal outcomes. The Janus face metaphor also allows for a prospective exploration of potential impacts of diabetes-related technology by patients, families, and their doctors so as to anticipate and minimize potential subsequent tensions.

双面神隐喻方法强调,一项技术可能同时具有两种相反的面孔或特性,在人机交互中具有不可预见的悖论。在使用糖尿病相关技术的青少年中,有时会出现不理想的接受度和临床结果。传统的线性技术决定模型将这些意外结果归因于次优技术、次优患者行为或次优结果测量。在过去的二十年中,这种模式在普遍改善临床结果方面并未取得成功。另一方面,双面神的隐喻脱离了线性的技术决定论模型,专注于人类条件和技术的动态相互作用。具体来说,它可以用来了解采用或成功使用糖尿病相关技术的差异,并回顾性地了解次优结果。两面脸的隐喻也允许对糖尿病相关技术的潜在影响进行前瞻性的探索,患者,家属和他们的医生,以预测和减少潜在的后续紧张。
{"title":"Adolescent ambivalence about diabetes technology-The Janus faces of automated care.","authors":"Fergus J Cameron,&nbsp;Michael Arnold,&nbsp;John W Gregory","doi":"10.1111/pedi.13423","DOIUrl":"https://doi.org/10.1111/pedi.13423","url":null,"abstract":"<p><p>The Janus face metaphor approach highlights that a technology may simultaneously have two opposite faces or properties with unforeseen paradoxes within human-technology interaction. Suboptimal acceptance and clinical outcomes are sometimes seen in adolescents who use diabetes-related technologies. A traditional linear techno-determinist model of technology use would ascribe these unintended outcomes to suboptimal technology, suboptimal patient behavior, or suboptimal outcome measures. This paradigm has demonstratively not been successful at universally improving clinical outcomes over the last two decades. Alternatively, the Janus face metaphor moves away from a linear techno-determinist model and focuses on the dynamic interaction of the human condition and technology. Specifically, it can be used to understand variance in adoption or successful use of diabetes-related technology and to retrospectively understand suboptimal outcomes. The Janus face metaphor also allows for a prospective exploration of potential impacts of diabetes-related technology by patients, families, and their doctors so as to anticipate and minimize potential subsequent tensions.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"23 8","pages":"1717-1724"},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/3d/PEDI-23-1717.PMC10091736.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9296997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ISPAD Clinical Practice Consensus Guidelines 2022: Managing diabetes in preschoolers. ISPAD临床实践共识指南2022:管理学龄前儿童糖尿病。
IF 3.4 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-12-01 DOI: 10.1111/pedi.13427
Frida Sundberg, Carine deBeaufort, Lars Krogvold, Susana Patton, Thereza Piloya, Carmel Smart, Michelle Van Name, Jill Weissberg-Benchell, Jose Silva, Linda A diMeglio
The Queen Silvia Childrens Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden Department of Pediatrics, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden Clinique Pédiatrique, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg Department of Pediatric Endocrinology, Universitair Ziekenhuis Brussel–Vrije Universiteit Brussel, Brussels, Belgium Paediatric Department, Oslo University Hospital, Oslo, Norway Center for Healthcare Delivery Science, Nemours Children's Health, Jacksonville, Florida, USA Department of Paediatrics & Child Health, School of Medicine, College of Health Sciences Makerere University, Kampala, Uganda Department of Paediatric Endocrinology and Diabetes, John Hunter Children's Hospital and School of Health Sciences, University of Newcastle, Newcastle, New South Wales, Australia Yale School of Medicine, New Haven, Connecticut, USA Department of Psychiatry and Behavioral Sciences, Ann & Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA SummitStone Health Partners, Fort Collins, Colorado, USA Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana, USA
{"title":"ISPAD Clinical Practice Consensus Guidelines 2022: Managing diabetes in preschoolers.","authors":"Frida Sundberg,&nbsp;Carine deBeaufort,&nbsp;Lars Krogvold,&nbsp;Susana Patton,&nbsp;Thereza Piloya,&nbsp;Carmel Smart,&nbsp;Michelle Van Name,&nbsp;Jill Weissberg-Benchell,&nbsp;Jose Silva,&nbsp;Linda A diMeglio","doi":"10.1111/pedi.13427","DOIUrl":"https://doi.org/10.1111/pedi.13427","url":null,"abstract":"The Queen Silvia Childrens Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden Department of Pediatrics, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden Clinique Pédiatrique, Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg Department of Pediatric Endocrinology, Universitair Ziekenhuis Brussel–Vrije Universiteit Brussel, Brussels, Belgium Paediatric Department, Oslo University Hospital, Oslo, Norway Center for Healthcare Delivery Science, Nemours Children's Health, Jacksonville, Florida, USA Department of Paediatrics & Child Health, School of Medicine, College of Health Sciences Makerere University, Kampala, Uganda Department of Paediatric Endocrinology and Diabetes, John Hunter Children's Hospital and School of Health Sciences, University of Newcastle, Newcastle, New South Wales, Australia Yale School of Medicine, New Haven, Connecticut, USA Department of Psychiatry and Behavioral Sciences, Ann & Robert H. Lurie Children's Hospital of Chicago, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA SummitStone Health Partners, Fort Collins, Colorado, USA Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana, USA","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"23 8","pages":"1496-1511"},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/4a/0c/PEDI-23-1496.PMC10108244.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9830506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Differences in retinopathy prevalence and associated risk factors across 11 countries in three continents: A cross-sectional study of 156,090 children and adolescents with type 1 diabetes. 三大洲 11 个国家视网膜病变患病率及相关风险因素的差异:一项针对 156,090 名 1 型糖尿病儿童和青少年的横断面研究。
IF 3.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-12-01 Epub Date: 2022-09-22 DOI: 10.1111/pedi.13416
Natasa Bratina, Marie Auzanneau, Niels Birkebaek, Carine de Beaufort, Valentino Cherubini, Maria E Craig, Dana Dabelea, Klemen Dovc, Sabine E Hofer, Reinhard W Holl, Elizabeth T Jensen, Dick Mul, Katrin Nagl, Holly Robinson, Ulrike Schierloh, Jannet Svensson, Valentina Tiberi, Henk J Veeze, Justin T Warner, Kim C Donaghue

Objective: To examine the prevalence, time trends, and risk factors of diabetic retinopathy (DR) among youth with type 1 diabetes (T1D) from 11 countries (Australia, Austria, Denmark, England, Germany, Italy, Luxemburg, Netherlands, Slovenia, United States, and Wales).

Subjects and methods: Data on individuals aged 10-21 years with T1D for >1 year during the period 2000-2020 were analyzed. We used a cross-sectional design using the most recent year of visit to investigate the time trend. For datasets with longitudinal data, we aggregated the variables per participant and observational year, using data of the most recent year to take the longest observation period into account. DR screening was performed through quality assured national screening programs. Multiple logistic regression models adjusted for the year of the eye examination, age, gender, minority status, and duration of T1D were used to evaluate clinical characteristics and the risk of DR.

Results: Data from 156,090 individuals (47.1% female, median age 15.7 years, median duration of diabetes 5.2 years) were included. Overall, the unadjusted prevalence of any DR was 5.8%, varying from 0.0% (0/276) to 16.2% between countries. The probability of DR increased with longer disease duration (aORper-1-year-increase  = 1.04, 95% CI: 1.03-1.04, p < 0.0001), and decreased over time (aORper-1-year-increase  = 0.99, 95% CI: 0.98-1.00, p = 0.0093). Evaluating possible modifiable risk factors in the exploratory analysis, the probability of DR increased with higher HbA1c (aORper-1-mmol/mol-increase-in-HbA1c  = 1.03, 95% CI: 1.03-1.03, p < 0.0001) and was higher among individuals with hypertension (aOR = 1.24, 95% CI: 1.11-1.38, p < 0.0001) and smokers (aOR = 1.30, 95% CI: 1.17-1.44, p < 0.0001).

Conclusions: The prevalence of DR in this large cohort of youth with T1D varied among countries, increased with diabetes duration, decreased over time, and was associated with higher HbA1c, hypertension, and smoking.

目的研究 11 个国家(澳大利亚、奥地利、丹麦、英格兰、德国、意大利、卢森堡、荷兰、斯洛文尼亚、美国和威尔士)1 型糖尿病(T1D)青少年糖尿病视网膜病变(DR)的患病率、时间趋势和风险因素:我们分析了 2000-2020 年间年龄在 10-21 岁之间、患 T1D 超过 1 年的人的数据。我们采用横断面设计,使用最近一年的就诊数据来研究时间趋势。对于有纵向数据的数据集,我们使用最近一年的数据对每个参与者和观察年份的变量进行了汇总,以考虑到最长的观察期。DR 筛查是通过有质量保证的国家筛查计划进行的。我们使用调整了眼科检查年份、年龄、性别、少数民族身份和 T1D 持续时间的多元逻辑回归模型来评估临床特征和 DR 风险:共纳入 156,090 人(47.1% 为女性,中位年龄为 15.7 岁,中位糖尿病病程为 5.2 年)的数据。总体而言,任何DR的未调整患病率为5.8%,不同国家的患病率从0.0%(0/276)到16.2%不等。随着病程的延长,发生 DR 的概率也会增加(aOR 每增加 1 年 = 1.04,95% CI:1.03-1.04,p 每增加 1 年 = 0.99,95% CI:0.98-1.00,p = 0.0093)。在探索性分析中评估了可能存在的可改变的风险因素,DR 的概率随着 HbA1c 的升高而升高(aOR per-1-mmol/mol-in-HbA1c increase = 1.03,95% CI:1.03-1.03,p 结论:DR 的发病率与 HbA1c 升高有关:在这个庞大的 T1D 青少年队列中,DR 的患病率因国家而异,随糖尿病病程的延长而增加,随时间的推移而降低,并且与 HbA1c 升高、高血压和吸烟有关。
{"title":"Differences in retinopathy prevalence and associated risk factors across 11 countries in three continents: A cross-sectional study of 156,090 children and adolescents with type 1 diabetes.","authors":"Natasa Bratina, Marie Auzanneau, Niels Birkebaek, Carine de Beaufort, Valentino Cherubini, Maria E Craig, Dana Dabelea, Klemen Dovc, Sabine E Hofer, Reinhard W Holl, Elizabeth T Jensen, Dick Mul, Katrin Nagl, Holly Robinson, Ulrike Schierloh, Jannet Svensson, Valentina Tiberi, Henk J Veeze, Justin T Warner, Kim C Donaghue","doi":"10.1111/pedi.13416","DOIUrl":"10.1111/pedi.13416","url":null,"abstract":"<p><strong>Objective: </strong>To examine the prevalence, time trends, and risk factors of diabetic retinopathy (DR) among youth with type 1 diabetes (T1D) from 11 countries (Australia, Austria, Denmark, England, Germany, Italy, Luxemburg, Netherlands, Slovenia, United States, and Wales).</p><p><strong>Subjects and methods: </strong>Data on individuals aged 10-21 years with T1D for >1 year during the period 2000-2020 were analyzed. We used a cross-sectional design using the most recent year of visit to investigate the time trend. For datasets with longitudinal data, we aggregated the variables per participant and observational year, using data of the most recent year to take the longest observation period into account. DR screening was performed through quality assured national screening programs. Multiple logistic regression models adjusted for the year of the eye examination, age, gender, minority status, and duration of T1D were used to evaluate clinical characteristics and the risk of DR.</p><p><strong>Results: </strong>Data from 156,090 individuals (47.1% female, median age 15.7 years, median duration of diabetes 5.2 years) were included. Overall, the unadjusted prevalence of any DR was 5.8%, varying from 0.0% (0/276) to 16.2% between countries. The probability of DR increased with longer disease duration (aOR<sub>per-1-year-increase</sub>  = 1.04, 95% CI: 1.03-1.04, p < 0.0001), and decreased over time (aOR<sub>per-1-year-increase</sub>  = 0.99, 95% CI: 0.98-1.00, p = 0.0093). Evaluating possible modifiable risk factors in the exploratory analysis, the probability of DR increased with higher HbA1c (aOR<sub>per-1-mmol/mol-increase-in-HbA1c</sub>  = 1.03, 95% CI: 1.03-1.03, p < 0.0001) and was higher among individuals with hypertension (aOR = 1.24, 95% CI: 1.11-1.38, p < 0.0001) and smokers (aOR = 1.30, 95% CI: 1.17-1.44, p < 0.0001).</p><p><strong>Conclusions: </strong>The prevalence of DR in this large cohort of youth with T1D varied among countries, increased with diabetes duration, decreased over time, and was associated with higher HbA1c, hypertension, and smoking.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"23 8","pages":"1656-1664"},"PeriodicalIF":3.9,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5d/3b/PEDI-23-1656.PMC9771999.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10293796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survival of children and youth with type 1 diabetes mellitus in Tanzania. 坦桑尼亚1型糖尿病儿童和青少年的生存率
IF 3.4 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2022-12-01 DOI: 10.1111/pedi.13425
Edna Siima Majaliwa, Linda Minja, Joel Ndayongeje, Kaushik Ramaiya, Sayoki G Mfinanga, Blandina T Mmbaga

Introduction: Survival from type 1 diabetes Mellitus is low in lower-income countries with underdeveloped health systems. Support programs from partners like life for a child (LFAC) and changing diabetes in children (CDiC) were implemented in Tanzania in 2005 to provide diabetes care to children and youth. No evaluation of survival has been done since their implementation.

Objective: To assess the survival of children and youth living with diabetes mellitus (CYLDM) in Tanzania.

Methods: A retrospective data collection from 39 clinics of CYLDM was done by extracting data from the diabetes registry between 1991 and 2019. Three cohort were analyzed (1) Cohort 1991-2004 (pre-implementation), (2) Cohort 2005-2010 (during implementation), and (3) 2011-2019 (after the implementation of LFAC/CDiC). Data were analyzed using STATA-version 14.

Results: A total of 3822 data of CYLDM were extracted, mean age at diagnosis was 13.8 (±5) years. Approximately fifty-one percent (50.8%) were male. The total observation time was 28 years, and the Median duration of diabetes of 5 (IQR2, 8) years. Total death was 95 (3%), with a mean age at death of 17.7 (SD 4.7) years. The last cohort (2011-2019) had more diagnosis 2353 (72.7%), as compared to the <2005 cohort with only 163(5%). The survival improved from 59% before 2005 to 69% in the last cohort (2011-2019).

Conclusion: The implemented programs have facilitated the diagnosis and retention of CYLDM in the health care system. In doing so, it has also increased the survival probability in Tanzania compared to the early 90s.

在卫生系统不发达的低收入国家,1型糖尿病患者的生存率较低。2005年,坦桑尼亚实施了“儿童生活”(LFAC)和“改变儿童糖尿病”(CDiC)等合作伙伴的支持项目,为儿童和青少年提供糖尿病护理。自实施以来,没有对生存情况进行评估。目的:评估坦桑尼亚儿童和青少年糖尿病患者(CYLDM)的生存率。方法:通过提取1991年至2019年糖尿病登记处的数据,回顾性收集39家CYLDM诊所的数据。分析了三个队列(1)1991-2004队列(实施前),(2)2005-2010队列(实施中)和(3)2011-2019队列(实施LFAC/CDiC后)。使用STATA-version 14分析数据。结果:共提取CYLDM资料3822例,平均诊断年龄为13.8(±5)岁。大约51%(50.8%)是男性。总观察时间28年,糖尿病中位病程5年(IQR2, 8)。总死亡95例(3%),平均死亡年龄17.7岁(SD 4.7)。最后一个队列(2011-2019)的诊断为2353例(72.7%),结论:实施的项目促进了CYLDM在医疗系统中的诊断和保留。在这样做的过程中,与90年代初相比,它也提高了坦桑尼亚的存活率。
{"title":"Survival of children and youth with type 1 diabetes mellitus in Tanzania.","authors":"Edna Siima Majaliwa,&nbsp;Linda Minja,&nbsp;Joel Ndayongeje,&nbsp;Kaushik Ramaiya,&nbsp;Sayoki G Mfinanga,&nbsp;Blandina T Mmbaga","doi":"10.1111/pedi.13425","DOIUrl":"https://doi.org/10.1111/pedi.13425","url":null,"abstract":"<p><strong>Introduction: </strong>Survival from type 1 diabetes Mellitus is low in lower-income countries with underdeveloped health systems. Support programs from partners like life for a child (LFAC) and changing diabetes in children (CDiC) were implemented in Tanzania in 2005 to provide diabetes care to children and youth. No evaluation of survival has been done since their implementation.</p><p><strong>Objective: </strong>To assess the survival of children and youth living with diabetes mellitus (CYLDM) in Tanzania.</p><p><strong>Methods: </strong>A retrospective data collection from 39 clinics of CYLDM was done by extracting data from the diabetes registry between 1991 and 2019. Three cohort were analyzed (1) Cohort 1991-2004 (pre-implementation), (2) Cohort 2005-2010 (during implementation), and (3) 2011-2019 (after the implementation of LFAC/CDiC). Data were analyzed using STATA-version 14.</p><p><strong>Results: </strong>A total of 3822 data of CYLDM were extracted, mean age at diagnosis was 13.8 (±5) years. Approximately fifty-one percent (50.8%) were male. The total observation time was 28 years, and the Median duration of diabetes of 5 (IQR2, 8) years. Total death was 95 (3%), with a mean age at death of 17.7 (SD 4.7) years. The last cohort (2011-2019) had more diagnosis 2353 (72.7%), as compared to the <2005 cohort with only 163(5%). The survival improved from 59% before 2005 to 69% in the last cohort (2011-2019).</p><p><strong>Conclusion: </strong>The implemented programs have facilitated the diagnosis and retention of CYLDM in the health care system. In doing so, it has also increased the survival probability in Tanzania compared to the early 90s.</p>","PeriodicalId":19797,"journal":{"name":"Pediatric Diabetes","volume":"23 8","pages":"1560-1566"},"PeriodicalIF":3.4,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10431884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
期刊
Pediatric Diabetes
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1